FDA reportedly granted GRAS status for one specific oral formulation but not for the injectable peptide
In a 2001 study published in Endocrinology , Heffernan and colleagues reported that chronic AOD-9604 administration reduced body weight gain, decreased adipose tissue mass, and increased fat oxidation in obese mice without altering IGF-1 levels or glucose metabolism effects that were abolished in beta3 adrenergic receptor (3-AR) knockout mice, implicating 3-AR signaling as the mechanism of action [1]
Annals of Clinical Biochemistry, 48(5), 418-432
Common research applications include: Obesity and Weight Loss Modeling: Studying the mechanisms of NNMT inhibition on fat oxidation and energy expenditure
For those with severe deficiencies, B12 injections may be an option to restore levels effectively
Together, they are commonly used to support active weight management and energy protocols